Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has before, explains Delve Therapeutics cofounder and CTO Mike Flanagan, Ph.D.
- BIO2025: Sanofi R&D, FDA's Martin Makary, Paying For New Therapies
- A New Prescription For R&D Tax Credit Reporting
- Structuring Cross Border China Biotech 'NewCo' Transactions
- Using Generative AI For Smarter, Faster, More Predictive Biopharma Ops
- EU Launches Strategic Bid to Attract R&D and Investments in Biotech
- Winning With The Right Marbles: The Future of Generics
- The Shift From LAL To Recombinant: What Your Lab Should Expect
- U.S. Tariffs And Their Tenuous Impact On Clinical Trials
COMPANIES TO WATCH
-
Companies To Watch: Vivani Medical
Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.
-
Imunon aims to shake up the standard of care in the frontline treatment of advanced ovarian cancer.
-
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.
-
Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small molecules.
WHERE ARE THEY NOW
-
Where Are They Now? Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and irritation in the eyelid. A new consumer DTC campaign, potential global approvals, and a new indication in the clinic could turn Xdemvy into a blockbuster drug.
-
Where Are They Now? Teva Pharmaceuticals
Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, and branded drugs to set the company back on track, or back to the future.
-
Where Are They Now? Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a smaller company than it was in 2016, when Life Science Leader wrote a feature article about its founder and mission. But Peter Hecht, Ironwood's former CEO, who now leads Tisento Therapeutics, has practiced what he preached.
NEWSLETTER ARCHIVE
- 06.30.25 -- Business Strategies For Trump 2.0 Policy Changes
- 06.30.25 -- Unlocking AI's Full Potential In Clinical Trials And Regulatory Success
- 06.27.25 -- Winning Management Strategies For Early And Late-Stage Drug Development
- 06.26.25 -- Streamline Your Scale-Up: Key Strategies For Biologics Manufacturing Success
- 06.25.25 -- Psychedelics For Mental Health Disorders
